Skip to content
Austin Top 50
Author:
Tangram Therapeutics PLC
Tangram Announces Oral Presentation of TGM-148 Preclinical Data Highlighting Context-Dependent Mechanism of Action at the American Society of Hematology (ASH) 2026 Annual Meeting
November 4, 2026
Tangram Announces First Participant Dosed in Phase 1 Trial of TGM-148, a Novel Investigational RNAi Medicine for Bleeding Disorders
October 29, 2026
Tangram Therapeutics Announces Progression to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial of TGM-312 and Appointment of Dr Sonya Montgomery as Chief Development Officer
September 3, 2026